Julie McCormick, MD
Internal Medicine · Anchorage, AKNPI 1124048384
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 68 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $737 and has fallen 98.2% since, to $13 in 2024.
Across 68 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$210
- Sanofi-aventis U.S. LLC$199
- Lilly USA, LLC$147
- Amgen$142
- AbbVie$129
- Takeda Pharmaceuticals U.S.A., Inc.$48
- plus $416 from 17 others
What the payments were for
- Food & beverage$1,292100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 9 | $210 |
| Sanofi-aventis U.S. LLC | 10 | $199 |
| Lilly USA, LLC | 9 | $147 |
| Amgen | 6 | $142 |
| AbbVie(2 entities) | 7 | $129 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
| Boehringer Ingelheim | 3 | $48 |
| GSK | 2 | $43 |
| Dexcom, Inc. | 3 | $37 |
| Regeneron Healthcare Solutions, Inc. | 2 | $35 |
| Novartis | 2 | $35 |
| Pfizer | 2 | $29 |
| Johnson & Johnson | 1 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| Medtronic | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Merck | 1 | $15 |
| AstraZeneca | 1 | $14 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolia$109
How this compares
$1,292 in reported general payments places this provider in the 80th percentile of 124 internal medicine providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 12 | $553 |
| Bupropion XlBupropion Hcl | 11 | $266 |
| Escitalopram Oxalate | 12 | $225 |
| Losartan Potassium | 11 | $210 |
| Hydroxyzine Hcl | 12 | $75 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Anchorage
- Loretta LeeAnchorage$8K
- Susan HeverlingAnchorage$6K
- Laurie MontanoAnchorage$6K
- Michele O FallonAnchorage$6K
- Alvaro RosalesAnchorage$4K
- Robin MillerAnchorage$4K
- Mary DemersAnchorage$3K
- Thuy-Trang NgoAnchorage$3K
- Irina GrimbergAnchorage$3K
- Brian TrimbleAnchorage$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.